Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics

John W. Devlin, Lynda S. Welage, Keith M. Olsen

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics'. Together they form a unique fingerprint.

Medicine & Life Sciences